Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as QAW039 capsules once daily for 28 days
QAW039 once daily for 28 days · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | QAW039 capsules once daily for 28 days |
| 2 | EXPERIMENTAL | Placebo to QAW039 capsules once daily for 28 days |
| 3 | EXPERIMENTAL | Fluticasone propionate inhaler twice daily for 28 days |
| Name | Type | Description |
|---|---|---|
| QAW039 capsules once daily for 28 days | DRUG | - |
| Placebo to QAW039 capsules once daily for 28 days | DRUG | - |
| Fluticasone propionate inhaler twice daily for 28 days | DRUG | - |
Inclusion Criteria: * Patients with a medical history of mild to moderate persistent allergic asthma. * Patients must weigh at least 45 kg to participate in the study, and must have abody mass index (BMI) of \>17 kg/m2. * Female patients must be surgically sterilized, postmenopausal or using a doub...
QAW039 once daily for 28 days is an investigational small molecule developed by Novartis AG for persistent asthma. It was studied as an oral capsule taken once daily over a 28-day treatment period in a Phase 2 clinical trial. It is not an approved therapy and remains in clinical development.
QAW039 once daily for 28 days was studied for the treatment of persistent asthma in adults. The Phase 2 trial enrolled patients with persistent asthma across the United States, Belgium, Germany, Romania, and South Korea. It is investigational and has not been approved for any indication.
Novartis AG (ticker NVS) is the developer of QAW039 once daily for 28 days. The company sponsored the Phase 2 trial evaluating the oral small molecule in persistent asthma. Novartis is the sole developer identified for this asset.
QAW039 once daily for 28 days is in Phase 2 development. The single completed trial, NCT01253603, was a Phase 2 study in persistent asthma. The drug is investigational and has not received FDA approval.
QAW039 once daily for 28 days has been evaluated in one completed Phase 2 trial, NCT01253603, titled Efficacy, Safety, and Pharmacokinetics of QAW039. The randomized, double-blind, controlled study enrolled 170 adults with persistent asthma across five countries. No active trials are ongoing.
Yes, QAW039 once daily for 28 days is also known as QAW039 capsules once daily for 28 days. Both names refer to the same oral small molecule formulation developed by Novartis AG for persistent asthma. The capsule form was administered once daily over 28 days in the Phase 2 trial.